Vantage Biosciences is developing an oral therapy targeting the AOC-3 pathway to treat non-proliferative diabetic retinopathy, a common complication of diabetes that can lead to vision loss. This approach aims to modify disease progression by addressing the underlying inflammatory mechanisms associated with the condition.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diabetic retinopathy, a common complication of diabetes, can lead to vision loss if left untreated. Current treatments often require invasive procedures and do not address the underlying inflammatory mechanisms driving disease progression in non-proliferative diabetic retinopathy (NPDR).
Solution
Vantage Biosciences is developing a novel oral therapy targeting the AOC-3 pathway to treat NPDR by addressing the root drivers of inflammation. This approach aims to modify the course of the disease by intervening at the earliest point of disease biology, potentially preventing or delaying vision loss. By targeting leukocyte trafficking and oxidative stress, the oral treatment offers a less invasive alternative to existing therapies, with the goal of improving patient access to disease-modifying treatments. The company is advancing its highly selective AOC-3 inhibitor into a Phase 2 clinical trial.
Target Audience
The primary target audience includes patients with non-proliferative diabetic retinopathy and the ophthalmologists and healthcare providers who manage their care.
Features
- Oral medication for ease of administration and improved patient compliance
- Selective AOC-3 inhibition to reduce inflammation in the retina
- Targets leukocyte trafficking and oxidative stress, key drivers of NPDR
- Designed to intervene at the earliest stages of disease biology